Henning Willers and colleagues found that PARP inhibitor by controlling ROS levels upon EGFR TKI treatment, promoted the sensitivity of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment [45]. Here, PARP1 is linked to lung cancer.